CenterBook Partners LP Invests $2.33 Million in GeneDx Holdings Corp. $WGS

CenterBook Partners LP purchased a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 17,893 shares of the company’s stock, valued at approximately $2,327,000.

Several other institutional investors also recently bought and sold shares of WGS. Jones Financial Companies Lllp lifted its stake in shares of GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after acquiring an additional 186 shares during the period. Quarry LP lifted its position in GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after purchasing an additional 209 shares during the period. Ramirez Asset Management Inc. acquired a new stake in GeneDx in the fourth quarter valued at about $33,000. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in GeneDx in the 4th quarter valued at approximately $35,000. Finally, Gordian Capital Singapore Pte Ltd purchased a new stake in GeneDx in the 3rd quarter valued at approximately $65,000. 61.72% of the stock is owned by institutional investors and hedge funds.

More GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Director Casdin Capital, LLC bought 50,000 shares at an average price of $52.86, adding to a recent buying streak that may signal confidence from a major insider. SEC filing
• Positive Sentiment: Casdin Capital also disclosed a larger purchase of 150,000 shares at $56.44 on June 4, reinforcing the impression of insider accumulation after the stock’s recent weakness. SEC filing
• Neutral Sentiment: GeneDx also presented at Goldman Sachs’ Global Healthcare Conference, which may have helped keep the stock in focus, but no major new operating update was highlighted in the transcript. Conference transcript
• Neutral Sentiment: Analyst sentiment remains mixed-to-positive overall, with the stock carrying an average “Moderate Buy” rating, though that view has not changed the near-term legal headline risk. Analyst rating update
• Negative Sentiment: Several law firms issued fresh class-action notices and lead-plaintiff reminders tied to GeneDx’s stock drop after its Q1 results, keeping investor attention on potential securities-fraud claims and litigation uncertainty. Class action alert
• Negative Sentiment: The lawsuits center on alleged misleading disclosures and a steep post-earnings selloff, which may continue to weigh on sentiment despite insider buying. Litigation report

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Piper Sandler reissued an “overweight” rating and set a $130.00 target price (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Weiss Ratings lowered GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Zacks Research downgraded GeneDx from a “strong-buy” rating to a “hold” rating in a report on Friday, April 24th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $75.00 price target (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Finally, Jefferies Financial Group set a $150.00 price target on shares of GeneDx in a report on Monday, February 23rd. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $96.43.

GeneDx Stock Performance

WGS opened at $56.33 on Wednesday. GeneDx Holdings Corp. has a 1-year low of $32.21 and a 1-year high of $170.87. The stock has a market cap of $1.67 billion, a P/E ratio of -21.02 and a beta of 1.96. The stock’s 50 day simple moving average is $55.24 and its 200 day simple moving average is $91.57. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95.

GeneDx (NASDAQ:WGS) last posted its earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The firm had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same quarter in the previous year, the firm posted ($0.23) earnings per share. As a group, equities analysts anticipate that GeneDx Holdings Corp. will post -1 EPS for the current fiscal year.

Insider Activity

In other GeneDx news, Director Casdin Capital, Llc acquired 50,000 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were purchased at an average cost of $52.86 per share, with a total value of $2,643,000.00. Following the purchase, the director owned 3,707,164 shares in the company, valued at approximately $195,960,689.04. The trade was a 1.37% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Keith A. Meister bought 46,273 shares of the company’s stock in a transaction on Friday, May 15th. The shares were acquired at an average price of $38.91 per share, with a total value of $1,800,482.43. Following the completion of the acquisition, the director directly owned 4,784,570 shares in the company, valued at $186,167,618.70. This represents a 0.98% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 2,256,420 shares of company stock worth $93,144,340 and sold 72,382 shares worth $4,889,473. 29.60% of the stock is owned by insiders.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.